Literature DB >> 12098628

The interaction index: a measure of drug synergism.

Ronald J Tallarida1.   

Abstract

Two drugs used in combination may produce enhanced or reduced effects. The degree of enhancement or reduction is measured from the interaction index (gamma), a quantity that indicates the changed potency of the combination. The index is therefore a quantitative marker for the drug combination and effect metric used. Methodology for measuring the interaction index utilizes the combination and individual drug dose-effect data suitably modeled by regression techniques that most often produce linear plots of effect on log dose from which isobolar analysis is employed. The isobologram provides a simple and convenient graphical assessment of the interaction index but an independent statistical analysis is needed to assess its precision. In some cases, the relative potency of the constituent drugs is the same at all effect levels. When this is so, it is shown that the interaction index can be measured by either an isobolar or an alternate method that is illustrated here. These calculations demonstrate that these different methods of analysis yield the same value of gamma, and do so with comparable precision.

Mesh:

Substances:

Year:  2002        PMID: 12098628     DOI: 10.1016/s0304-3959(02)00041-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  59 in total

Review 1.  Revisiting the isobole and related quantitative methods for assessing drug synergism.

Authors:  Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2012-04-17       Impact factor: 4.030

2.  Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-14       Impact factor: 3.000

Review 3.  The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Authors:  Robert B Raffa; Joseph V Pergolizzi; Ronald J Tallarida
Journal:  J Pain       Date:  2010-03-24       Impact factor: 5.820

Review 4.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

5.  Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects.

Authors:  Barak W Gunter; Sherman A Jones; Ian A Paul; Donna M Platt; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2016-06-29       Impact factor: 4.530

6.  Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord.

Authors:  Aaron C Overland; Kelley F Kitto; Anne-Julie Chabot-Doré; Patrick E Rothwell; Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  J Neurosci       Date:  2009-10-21       Impact factor: 6.167

7.  Binding site location on GABAA receptors determines whether mixtures of intravenous general anaesthetics interact synergistically or additively in vivo.

Authors:  Daniel E Kent; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

8.  Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.

Authors:  Aruna V Krishnan; Srilatha Swami; Lihong Peng; Jining Wang; Jacqueline Moreno; David Feldman
Journal:  Endocrinology       Date:  2009-11-11       Impact factor: 4.736

9.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

10.  Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.

Authors:  Barak W Gunter; Donna M Platt; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2015-08-06       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.